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Torrent technology, but our filtering strategy can be applied 
to reduce erroneous variants.
Background
Whole exome sequencing (WES) is a powerful method ide-
ally designed to rapidly investigate all the coding sequences 
in human genome at base resolution, allowing to detect a 
wide spectrum of genetic variations (Adams et al. 2012; 
Wang et al. 2013; Samarakoon et al. 2014). Lowering costs 
of next generation sequencing (NGS) led to exponential 
increase of WES-based studies and this kind of approach 
has rapidly become the first-choice option to discover new 
disease genes in rare Mendelian disorders (Gilissen et al. 
2011; Bamshad et al. 2011), as well as to evaluate risk 
alleles in complex disorders (Kiezun et al. 2012; Do et al. 
2012). Recently, WES has been also increasingly applied in 
clinical and diagnostic settings (Yang et al. 2013; Biesecker 
and Green 2014; Lee et al. 2014), especially for cancer, 
pathologies with high genetic heterogeneity or in clinical 
cases where causative genes could not be clearly hypoth-
esized. However, application of WES to clinical settings 
has some special requirements, such as increased sensitiv-
ity, full target sequence representation and the ability to 
rapidly perform sequencing with acceptable costs also for 
one or few samples (Dewey et al. 2014; Kim et al. 2015; 
Taylor et al. 2015). Increasing interest resulted in the devel-
opment of several commercial exome enrichment products 
from different companies, such as Agilent, Nimblegen, Life 
Technologies and Illumina, mostly based on capture probes 
approach (Bodi et al. 2013; Chilamakuri et al. 2014). Simi-
larly, several NGS sequencers based on different technolo-
gies are available to perform WES.h Sequence by synthesis 
with fluorescent reversible terminators from Illumina and 
Abstract The Ion Proton platform allows to perform 
whole exome sequencing (WES) at low cost, providing 
rapid turnaround time and great flexibility. Products for 
WES on Ion Proton system include the AmpliSeq Exome 
kit and the recently introduced HiQ sequencing chemistry. 
Here, we used gold standard variants from GIAB consor-
tium to assess the performances in variants identification, 
characterize the erroneous calls and develop a filtering 
strategy to reduce false positives. The AmpliSeq Exome 
kit captures a large fraction of bases (>94 %) in human 
CDS, ClinVar genes and ACMG genes, but with 2,041 
(7 %), 449 (13 %) and 11 (19 %) genes not fully repre-
sented, respectively. Overall, 515 protein coding genes 
contain hard-to-sequence regions, including 90 genes from 
ClinVar. Performance in variants detection was maxi-
mum at mean coverage >120×, while at 90× and 70× we 
measured a loss of variants of 3.2 and 4.5 %, respectively. 
WES using HiQ chemistry showed ~71/97.5 % sensitiv-
ity, ~37/2 % FDR and ~0.66/0.98 F1 score for indels and 
SNPs, respectively. The proposed low, medium or high-
stringency filters reduced the amount of false positives by 
10.2, 21.2 and 40.4 % for indels and 21.2, 41.9 and 68.2 % 
for SNP, respectively. Amplicon-based WES on Ion Pro-
ton platform using HiQ chemistry emerged as a competi-
tive approach, with improved accuracy in variants identi-
fication. False-positive variants remain an issue for the Ion 
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semiconductor sequencing from Life Technologies are the 
most adopted solutions nowadays (Metzker 2009; Jüne-
mann et al. 2013; Boland et al. 2013).
The semiconductor-based sequencing technology, 
launched in 2011 by Life Technologies (Rothberg et al. 
2011; Merriman et al. 2012) and implemented in Ion Tor-
rent NGS platforms, has emerged as an interesting alterna-
tive to Illumina-based sequencing, with the potential to be 
cost-effective and provide rapid turnaround time and greater 
flexibility in throughput. Indeed, the Ion Proton instrument, 
with 10-15 Gb output per run, enables investigators to study 
exomes, transcriptomes and custom target regions rapidly 
and at low cost (Jünemann et al. 2013; Boland et al. 2013). 
Several improvements have been recently delivered by Life 
Technologies for WES studies on the Ion Proton platform. 
In 2012 the company developed the AmpliSeq Exome kit, 
the first commercial method to perform target enrichment 
of the entire human exome by multiplex-PCR amplifica-
tion, reducing time for library preparation. This method uses 
ultra-high multiplex-PCR approach based on the proprietary 
AmpliSeq technology to generate about 294,000 amplicons 
covering ~97 % of the bases in coding exons of human 
genes. In 2015, the company released the HiQ sequencing 
chemistry to improve accuracy of indel detection. Indeed, 
past comparisons of WES performed on Ion Proton and Illu-
mina platforms revealed that the former performs with high 
accuracy at SNP discovery, but has a high ratio of false posi-
tives in the identification of small indels (Jünemann et al. 
2013; Boland et al. 2013; Zhang et al. 2015). This posed 
serious challenges in downstream data analysis, consider-
ing that most work-flows search for variants that potentially 
alter gene function, particularly loss of function variants 
like indels and stop-gain mutations (Cooper and Shendure 
2011; Isakov et al. 2013; Wang and Xing 2013). Since the 
vast majority of WES studies have been performed on Illu-
mina sequencers, most technical optimization studies have 
focused on that particular platform (Chilamakuri et al. 2014; 
Head et al. 2014; van Dijk et al. 2014). Similarly, most bio-
informatic methods are optimized for analysis of Illumina-
based data (Hatem et al. 2013; Ross et al. 2013; Pabinger 
et al. 2013; Ghoneim et al. 2014; Yi et al. 2014; Laehne-
mann et al. 2015), while strategies to improve data analysis 
and variants identification on Ion Torrent platforms have not 
been discussed in detail so far.
Overall, an independent analysis of WES performance 
on Ion Proton sequencer using AmpliSeq Exome kit and 
the latest HiQ chemistry and a detailed comparison with 
Illumina-based results are still lacking, as well as alterna-
tive strategies for data analysis and filtering of false-posi-
tive variants.
Thus, we decided to perform a detailed technical evalu-
ation of sequencing performances based on a dataset of 
34 exomes produced using AmpliSeq Exome kit and Ion 
Proton platform. Moreover, we compared WES data from 
the NA12878 human reference sample obtained with v3 
and HiQ chemistries to assess improvements in variants 
identification and characterize the properties of erroneous 
calls. This sample has been deeply characterized through 
time using multiple sequencing and genotyping platforms, 
and in 2013 Genome in a Bottle Consortium (GIAB), 
part of the National Institute of Standards and Technol-
ogy (NIST), has distributed the first set of gold standard 
calls based on integration of 13 different datasets of this 
sample obtained using different NGS technologies (Zook 
et al. 2014). This constantly updated set of variants is now 
broadly accepted as a standard for variant identification 
benchmarking. By comparing our results with gold stand-
ard variants provided by GIAB (Zook et al. 2014), we ana-
lyzed in detail the performance of variants identification for 
both SNPs and indels and developed a filtering strategy to 
reduce false-positive calls.
Materials and methods
Comparison of target regions across different exome 
capture kits
The list of target regions included in the capture kits was 
obtained in BED file format from the vendor site for 
AmpliSeq Exome (Life Technologies), SeqCap EZ Exome 
v2/v3 (Roche) and SureSelect Human All Exon v5/v6 
(Agilent). The full list of CDS coding exons from RefSeq 
was obtained from UCSC Genome Browser, corresponding 
to CCDS release 17 (CDS list). The list of clinically rele-
vant genes was obtained from ClinVar database on 30 April 
2015. We included in our analysis only genes reported 
as pathogenic, likely pathogenic, risk factors, or drug 
response and annotated with a gene symbol, for a total of 
3399 genes (ClinVar list). Another list was created includ-
ing the 56 genes indicated by the American College of 
Medical Genetics in the list of actionable genetic findings 
to be reported to patients when performing exome sequenc-
ing analysis (ACMG list) (Green et al. 2013). Coordinates 
of coding exons of the genes in each list were obtained in 
BED file format from the UCSC Genome Browser. Using 
BEDtools (Quinlan and Hall 2010), we compared each 
kit target regions with CDS, ClinVar and ACMG lists to 
determine the fraction of bases addressed and the number 
of genes that have at least one exon partially or fully not 
addressed.
Exome sequencing
Exome sequencing was performed for 34 subjects using 
Ion Proton platform (Life Technologies) and AmpliSeq 
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Exome kit (Life Technologies) for library preparation. 
Briefly, 100 ng of gDNA was used as starting material in 
the AmpliSeq Exome amplification step following manu-
facturer’s protocol. The final sequencing libraries were 
inspected and quantified using Bioanalyzer 2100 instru-
ment and DNA HS kit (Agilent Technologies). All librar-
ies were diluted to 100 pM working solutions and then 
pooled as needed to perform the template preparation on 
Ion OneTouch 2 (Life Technologies) according to manu-
facturer’s protocols. Of the reported 27 sequencing runs: 
the first 15, including 24 samples, were performed using 
Ion PI Template OT2 200 v2 and Ion PI Sequencing 200 
v2 kits (Life Technologies); 5 runs, including 10 samples, 
were performed with v3 of the same kits; 5 runs, including 
9 samples, were performed using Ion PI Hi-Q OT2 200 kit 
and Ion PI Hi-Q Sequencing 200 kit. Templated Ion Sphere 
Particles (ISP) were then enriched for positive ISP using 
Ion OneTouch ES (Life Technologies) and sequenced on 
Ion Proton sequencer using Ion PI chip v2 or v3 (Life Tech-
nologies), as reported in Supplementary table 7. Basecall-
ing and sequence alignment were performed for all samples 
using Ion Torrent Suite software v.4.4.0.6 and genetic vari-
ants were then identified using Torrent Suite Variant Caller 
pipeline v.4.4.0.6 (TVC) with the optimized parameters 
provided by the manufacturer for AmpliSeq Exome.
The NA12878 reference gDNA was obtained from Cori-
ell Cell Repositories and used to produce an AmpliSeq 
Exome library with the same procedure described above, 
except for library quantification that was performed using 
RealTime PCR and Ion Library TaqMan Quantification kit 
(Life Technologies). The same library was then sequenced 
twice with the v3 version of the Ion PI Template OT2 200 
and Ion PI Sequencing 200 kits and one full Ion PI v2 chip; 
once using HiQ version of the kits and one full Ion PI v3 
chip.
Variants identification in public datasets
Aligned reads in BAM file format from eight independent 
exome sequencing experiments performed on NA12878 DNA 
using AmpliSeq Exome and the new HiQ sequencing chemis-
try were obtained from the Ion Community repository (https://
ioncommunity.lifetechnologies.com/docs/DOC-9389). 
Genetic variants were then identified using TVC v.4.4.0.6 and 
the optimized parameters provided by the manufacturer for 
AmpliSeq Exome.
Exome sequencing data on the NA12878 using Illu-
mina platform were obtained from 1000G repository (ftp://
ftp-trace.ncbi.nih.gov/1000genomes/ftp/technical/work-
ing/20120117_ceu_trio_b37_decoy/). This BAM file was 
already modified for duplicate removal, realignment around 
indels and base quality score recalibration, according to 
GATK best practices. Genetic variants were identified 
using GATK HaplotypeCaller v3.2-2 (DePristo et al. 2011) 
with default parameters, but-stand-emit-call set to 20.
Assessing coverage influence on variants identification
All the BAM files from the 15 non-HiQ samples with mean 
coverage above 90 were downsampled randomly using 
SAMtools (Li et al. 2009) to generate new alignments at 
8 levels of coverage: 90, 80, 70, 60, 50, 40, 30 and 20× 
mean coverage. Depth and breadth of coverage over the 
AmpliSeq Exome target regions were calculated for all the 
280 generated BAM files using BEDtools coverage func-
tion. Genetic variants identification was performed on each 
file using the command-line implementation of the TVC. 
In-house developed Perl/R scripts were used to compute 
distribution of variants and base coverage across various 
simulations and determine the relationship between cover-
age parameters and variants identification results.
To confirm the results from our simulations and verify 
that the same assumptions are validated for HiQ chemis-
try-based samples, we downsampled the nine BAM files 
of NA12878 sequenced with HiQ to 90 and 70× mean 
coverage, performed variants identification with the TVC 
and then compared results with those obtained using the 
full dataset, performing specificity and sensitivity tests as 
described below in “Study of performance” section.
Analysis of hard‑to‑sequence regions in AmpliSeq 
Exome
We used BEDtools to generate a subset of the CDS list, 
including only exons present in the AmpliSeq Exome 
design, and calculated the breadth of coverage across 
the targeted coding exons for all our 34 sequenced sam-
ples. Comparing the coverage results, we identified the 
exons that are always absent from sequencing data (frac-
tion of covered bases equal to zero) or always poorly cov-
ered, showing a fraction of covered bases ≤0.1, 0.25 or 
0.5. Since the AmpliSeq Exome kit is composed by about 
294,000 different PCR amplicons, we also characterized 
the coverage over each amplicon to identify those dis-
playing poor sequencing results across different samples. 
Using BEDtools coverage and nuc functions, we calcu-
lated the amplicons mean coverage across all samples and 
studied the relationship between amplicons coverage and 
their GC content. For each amplicon we also calculated the 
proportion of reads that is captured in the overall dataset, 
expressed as the ratio between reads of the amplicon and 
million total reads. This will provide a better estimation of 
how different amplicons are represented in the sequencing 
experiments.
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Study of performances in variants identification 
for HiQ chemistry
To evaluate the performances of HiQ-based experiments in 
terms of detected variants, we compared our results with 
the set of reference variants identified in the NA12878 
sample by GIAB consortium and provided as true vari-
ants dataset for benchmark (Zook et al. 2014). NIST v2.19 
true variant calls in high confident regions were obtained 
from GIAB repository (ftp://ftp-trace.ncbi.nih.gov/giab/
ftp/release/NA12878_HG001/NISTv2.19/) and used in our 
analysis.
We then compared variants identified by the consortium 
with those identified in our experiments performed using 
v3 chemistry and HiQ chemistry, as well as with variants 
identified in the HiQ datasets from Ion Community and in 
the Illumina dataset.
First of all, to ensure the best uniformity in variants rep-
resentation, all VCF files were normalized by splitting vari-
ants with multiple variant alleles and left aligning indels. 
We then restricted the analyzed variants to those falling 
in the high confident region as determined by GIAB and 
located within the AmpliSeq Exome target regions. Finally, 
since we were interested in performance on coding regions, 
we limited the considered variants to those located in the 
CDS regions plus three flanking base pairs.
Indel and SNP variants from each dataset were then 
compared separately with the GIAB reference calls to iden-
tify false positives, true positives and false negatives. We 
also compared false positive, true positive and false nega-
tive variants across the nine different HiQ datasets to deter-
mine systematic errors and reproducibility of true calls.
Characterization of errors in variant calling
To better evaluate erroneous calls and dissect possible 
sources of error, we studied several parameters in false-
positive and false-negative calls for both indel and SNP 
variants identified using HiQ chemistry. In details, for 
false-positive variants we analyzed the distribution of 
11 parameters calculated by the TVC and reported in the 
VCF files: alternate allele observation (AO), read depth 
(DP), flow-space alternate allele observations (FAO), 
flow space read depth (FDP), flow evaluator failed reads 
ratio (FXX), genotype quality (GQ), length of homopoly-
mer (HRUN), quality per read length (QD), variant qual-
ity (QUAL), strand bias ratio (STB) and strand bias p 
value (STBP). Moreover, we determined which propor-
tion of these variants was present as multiallelic variant 
calls in the original VCF file. For false-negative variants, 
where TVC information is missing, we evaluated the pro-
portion of missed calls due to low read depth (<10 reads) 
and indels calls were also inspected to identify possible 
recurrent motifs. Moreover, for both false-positive and 
false-negative indels we also considered indels length 
distribution. Finally, we used Perl scripts to intersect the 
dataset of false positives, false negatives and true posi-
tives from single experiments to evaluate if sequencing 
errors would be recurrent across different samples. For 
this analysis, we matched only variants that recur identi-
cal across the nine HiQ dataset, namely variants present-
ing the same position as well as identical reference and 
alternate alleles.
Determining filtering strategy for indel and SNP 
false‑positive variants
Based on the distribution of parameters described above, 
we selected five that could better discriminate false-posi-
tive from true-positive variants and generated ROC curves, 
separately for SNP and indels. For SNPs we used FAO, 
FDP, GQ, QUAL, STB; for indels: FAO, FDP, GQ, HRUN, 
QUAL. Using the eight datasets from Ion Community as 
training set we studied the effect of various combinations 
of these five parameters and created a false-positive fil-
ter with three different threshold of retained true-positive 
calls: high, medium and low-stringency filters which would 
retain >90, >95 and >99 % of true positives, respectively 
(Table 3). Moreover, we evaluated additional strategies 
to rank the robustness of identified indels based on their 
length and occurrence as multiallelic variants.
The filtering settings we defined were then applied 
on the HiQ data produced in our laboratory to test if this 
strategy could produce the desired results on samples not 
belonging to the training set.
Results
Characterization of AmpliSeq Exome and analysis 
of target regions
The AmpliSeq Exome kit (Life Technologies) uses a 
multiplex-PCR approach to simultaneously generate 
about 294,000 amplicons designed on CDS sequences of 
the human genome (Table 1). Size of amplicons ranges 
between 156 and 240 bp (Fig. 1a) and the kit design 
addresses 300,887 CDS exons, 61.5 % of whom are cov-
ered by a single amplicon (Fig. 1b). To better determine 
the actual content of target regions and the extent of non-
addressed clinically relevant regions, we compared the 
target intervals of AmpliSeq Exome kit with those of 
other popular exome capture kits, namely Life Technolo-
gies TargetSeq, Agilent SureSelect and Roche SeqCap EZ 
Exome. As described in methods, we determined for each 
kit the fraction of CDS bases comprised in the design and 
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Table 1  AmpliSeq exome kit 
main properties











293,903 24,492 206/156/240 57.74 97.5 % 298,901
Fig. 1  AmpliSeq exome properties and target region analysis. a 
Length density distribution calculated from the dimension of ampli-
cons generated with the AmpliSeq Exome kit as determined from the 
provided BED. In the kit design, most of the CDS exons are covered 
by a single amplicon (b). The comparison of target regions across 6 
different enrichment kits (c) revealed that no one fully address all the 
human CDS nor relevant clinical genes. The bar graph represents the 
number of genes with at least one exon partially addressed (green) 
or completely missed (red). Compared exome capture kits include: 
AmpliSeq Exome and TargetSeq Exome (Life Technologies), SureSe-
lect Human All Exon v5/v6 (Agilent Technologies) and SeqCap EZ 
v2/v3 (Roche)
extrapolated the number of genes not fully addressed, with 
particular interest on ClinVar pathological genes and the 
56 genes included in the incidental findings recommended 
report by ACMG. AmpliSeq Exome target regions covered 
a high proportion of bases in human CDS (97.5 %), ClinVar 
genes (94.1 %) and ACMG genes (98.9 %). However, even 
this small fraction of missed bases resulted in several genes 
with at least one exon completely missed: 2041 (7 %), 449 
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(13 %) and 11 (19 %) genes show this issue in human CDS, 
ClinVar and ACMG gene list, respectively (Fig. 1c). An 
example of a gene not completely addressed is reported in 
Supplementary figure 1a. Detailed statistics calculated for 
each exome enrichment kit are reported in supplementary 
file 1 and the complete list of the exons not fully addressed 
is provided in supplementary tables 1–6.
Sequencing results on Ion Proton platform
In our dataset of 27 sequencing experiments on Ion Proton 
platform the final throughput obtained from a single PI chip 
varies from 6 up to almost 18 Gb, with a mean through-
put of 9.3 and 11.5 Gb using PI v2 chip and chemistry v2 
and v3, respectively. Sequencing runs using PI v3 chip 
and HiQ chemistry resulted in 16.9 Gb mean through-
put (supplementary table 7). The whole protocol, from 
library preparation to sequence production, was completed 
in 48–60 h. Detailed results of exome sequencing on the 
34 samples included in this study are reported in supple-
mentary table 8. Mean coverage per sample was 42–148× 
and mapped reads were 21.7–53.9 M. AmpliSeq Exome 
enrichment protocol resulted in >85 % on-target reads for 
all samples except S25, with a percentage of target bases 
covered at least 20× of 72.1–94.4 %. Uniformity of cov-
erage, defined as the percentage of bases in target regions 
with a read depth at least 20 % of the average sample cov-
erage, is >80 % for all samples except S4 and S6. Cover-
age uniformity is confirmed also by inter-quartile range of 
base coverage (IQR), as reported in supplementary table 8. 
These data resulted in a number of identified variants 
between 42,555 and 54,127 using the Torrent Variant Caller 
(TCV) with the optimized parameters provided by the man-
ufacturer (see “Materials and methods”).
Coverage across target regions and characterization 
of problematic regions
Given a correct read length distribution of input library, 
the AmpliSeq Exome method showed a high uniformity of 
coverage across all samples (supplementary table 8). The 
fraction of target exons fully covered is >90 % in all sam-
ples except sample S4, with a mean of 96.8 %, even for 
samples with mean coverage as low as 40× (Supplemen-
tary figure 2a).
We then analyzed the coverage obtained per single 
amplicon to identify those that are hard to be sequenced and 
possible factors influencing sequencing performance. Mean 
coverage per amplicon ranges from 0.03 to 8886, with each 
amplicon capturing a fraction of the total throughput from 
0.01 to 167 reads/million reads (Supplementary figure 2b). 
Looking at the distribution of % GC across amplicons, there 
are 5458 and 2156 amplicons with  % GC >75 (high GC) 
and <25 (low GC), respectively (Supplementary figure 2c). 
Amplicons with high GC content have a median coverage 
of 14.2 and 41.8 % have mean coverage <10, while ampli-
cons with low GC content have a median coverage of 114 
and only 1.4 % have mean coverage <10. We found 3691 
amplicons (1.2 %) with a mean coverage <10 across all the 
sequenced samples, each one represented by <0.2 reads/
million reads. Of these amplicons 2282 (62 %) are char-
acterized by high GC content (>75 %). Instead, amplicons 
with GC content <25 % did not show a particular coverage 
bias and they represent only 31 (0.8 %) of the low covered 
amplicons (Supplementary figure 2d).
Besides high GC content, other factors influence 
sequence coverage. Detailed analysis of the sequences 
included in target regions and affected by coverage issues, 
revealed that some of them are consistent across all sam-
ples. In detail, 509 CDS exons resulted always covered 
by less than 10 reads; 51, 15 and 7 CDS exons resulted 
always partially sequenced with <50, 25 and 10 % of 
their sequence addressed, respectively. Moreover, in seven 
exons we found portions always missed by sequencing. 
This resulted in 515 protein coding genes containing hard-
to-sequence regions, including also 90 known pathogenic 
genes reported in ClinVar. An example is reported in Sup-
plementary figure 1b. The complete list of exons hard to be 
sequenced is reported in supplementary table 9.
Coverage effects on variant calling
In each sample the number of variants identified is, as 
expected, strongly influenced by coverage metrics, particu-
larly by the fraction of bases covered at least 20× (Supple-
mentary figure 3). Downsampling approach allowed us to 
better estimate the relationship between coverage metrics 
and performances in variant calling. Our analysis showed 
that, given a library with correct read length distribution, 
in each sample the fraction of bases covered at least 20× 
is exponentially related to the mean coverage (r2 = 0.974), 
with a marked decline below 50× and a maximum reached 
above 120× mean coverage (Supplementary figure 4a). 
Analysis of the fraction of variants lost at various down-
sampling steps showed a linear relationship (r2 = 0.986) 
with the fraction of bases covered at least 20× (Supple-
mentary figure 4b).
We then calculated the expected performance for a sam-
ple sequenced at 130×, 90× and 70× mean coverage. That 
would correspond to an experimental design with 2, 3 or 
4 exomes sequenced on a single PI chip v3, considering 
an optimal throughput of 16 Gb. Based on the generated 
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Table 2  NA12878 exome datasets used in the study
The table reports the results of the 11 exome sequencing experiments on the NA12878 sample used in the study. The source of the data is indi-
cated as Local, when specifically produced for this study, or Ion community, when downloaded from public repository
Sample Source Chemistry/chip Gb Mean coverage % of bases covered ≥20X Variants Mapped reads
NA12878_1 Local v3/v2 8.4 123 89.7 52,429 49,404,723
NA12878_2 Local v3/v2 10.9 160 91.6 52,820 70,938,267
NA12878_HiQ Local HiQ/v3 14.2 211 96.9 55,289 82,542,306
HiQ_012 Ion community HiQ/v3 7.2 125 94.7 53,703 42,829,518
HiQ_018 Ion community HiQ/v3 7.3 126 94.9 53,367 41,924,486
HiQ_022 Ion community HiQ/v3 9.7 168 96.5 53,721 54,412,206
HiQ_029 Ion community HiQ/v3 8.8 152 95.5 53,691 49,108,758
HiQ_030 Ion community HiQ/v3 8.8 152 95.5 53,640 48,942,525
HiQ_036 Ion community HiQ/v3 6.7 116 94.4 53,655 39,157,852
HiQ_042 Ion community HiQ/v3 8.2 142 95.9 53,594 45,781,947
HiQ_046 Ion community HiQ/v3 8.7 151 96.2 53,651 48,364,571
distributions, a sample covered 130× or more will result 
in >92 % bases covered at least 20× and ensures maximum 
performance in variants detection. Downsampling to 90× 
and 70× produces 90.1 and 87.2 % bases covered >20× 
resulting in 3.2 and 4.5 % loss of variants, respectively 
(Supplementary figure 4). These estimations were con-
firmed by downsampling to 90 and 70× mean coverage the 
nine NA12878 datasets generated on Ion Proton platform. 
Overall, 96.4–98.7 and 94.9–97.6 % of total variants were 
retained when downsampling to 90 and 70×, respectively. 
To better evaluate the impact of downsampling we also 
calculated the concordance with the gold standard GIAB 
calls as described in methods. After downsampling to 90×, 
we detected 0.9–5.5 and 0.5–1.4 % loss in true-positive 
variants for indels and SNPs, respectively. Instead, down-
sampling to 70× resulted in 4.3–8.8 and 1.1–2.2 % loss 
Fig. 2  Accuracy of variant identification. The performance of variant 
identification was assessed separately for indel (a) and SNP variants 
(b) by comparing the variants identified on the Ion Proton platform 
with the gold standard calls provided by GIAB consortium for sam-
ple NA12878. The comparison was conducted on samples sequenced 
using the v3 chemistry and the PI v2 chip, as well as the HiQ chem-
istry and the PI v3 chip. Results were also compared with those 
obtained using an Illumina-based exome sequencing of NA12878. 
The total number of variants in the GIAB and tested datasets are 
reported in brackets and the % of variants overlapping or unique to 
each compared dataset are shown in the Venn diagrams. Accuracy sta-
tistics are also reported for each comparison
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in true-positive variants for indels and SNPs, respectively 
(Supplementary figure 5).
Estimation of accuracy in variants identification
We estimated the accuracy of variants identification for the 
NA12878 reference sample by comparing the datasets of 
variants identified by Ion Proton platform (Table 2) with 
the set of gold standard variants reported by GIAB con-
sortium. The dataset of variants from GIAB addressed by 
AmpliSeq Exome kit within CDS sequences was composed 
by 325 indels and 15,811 SNPs. The dataset produced 
by Ion Proton platform accounted for ~790/370 indels 
and ~15,250/15,800 SNPs for v3 and HiQ chemistry data, 
respectively. Data produced with HiQ chemistry and PI v3 
chip showed a significant increase in accuracy compared to 
those produced using v3 chemistry and PI v2 chip. Results 
for SNP variants are now similar, with slightly better sen-
sitivity, to those obtained from the Illumina dataset, while 
false-positive indels remain markedly higher in the HiQ 
dataset with and FDR value up to 47 % (Fig. 2). Detailed 
results on variants identification performances for each 
dataset are reported in Supplementary table 10.
Analysis of false‑positive and false‑negative variants 
in the HiQ datasets
To investigate the nature of errors in variants identifica-
tion on the Ion Proton platform, we performed a detailed 
characterization of both false-positive and false-negative 
Fig. 3  Analysis of variant 
calling errors in HiQ datasets. 
A detailed characterization 
of errors in variants identi-
fied by the TVC using the 
optimize parameters provided 
by the manufacturer. a Frac-
tion of true-positive (red) and 
false-positive (black) variants 
occurring with more than 2 or 
more than 3 alternate alleles in 
the corresponding VCF file. b 
Fraction of false-negative SNP 
(blue) and indels (green) with 
read depth <10 in the cor-
responding sample. The indel 
length of false positive (red), 
true positive (green) and false 
negative (blue) calls identified 
across the nine HiQ datasets 
is analyzed in c. True posi-
tive calls are highly consistent 
across the nine HiQ samples, 
while false-positive calls are 
often run specific as suggested 
by the density plot (d), that evi-
dences the recurrence of false 
positives (red) and true positives 
(green)
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variants described above. We first evaluated the distribution 
of 11 parameters reported by the Torrent Variant Caller (see 
“Materials and methods”) across false-positive and true-
positive variants for indels and SNPs separately (Fig. 4). 
Moreover, we assessed the proportion of false-positive and 
true-positive variants represented as multiallelic variant 
calls in the original VCF file. Concerning indels, variants 
occurring with three or more alternate alleles represented 
8.5–12.5 % of false positives and only 0–0.4 % of true 
positives (Fig. 3a). No significant differences were detected 
for SNP variants (data not shown). For false-negative 
variants, we evaluated the proportion of missed calls due 
to low read depth (<10 reads), showing that 26–41 % of 
false-negative SNPs and 10–23 % of false-negative indels 
are due to low coverage (Fig. 3b). Further inspection of 
the false-negative calls with read depth >10× revealed that 
triplet repetition and homopolymeric regions are recur-
rent among missed variants (data not shown). Analysis of 
the indels length showed that most false positives and false 
negatives are represented by short (1–2 bp) insertion/dele-
tions, while large ones above 100 bp are almost all erro-
neous calls (Fig. 3c). We then compared read length distri-
bution and variant identification performances in the nine 
HiQ datasets. The NA12878_HiQ dataset, that showed 
lower performances in variant identification (see Supple-
mentary table 10), revealed a substantial deviation from the 
expected distribution with a loss of long fragments (Sup-
plementary figure 6).
Finally, we analyzed the recurrence of false-positive 
and true-positive variants across the nine HiQ datasets. 
True-positive variants were consistent through the datasets 
and 81 % were found in at least 8 samples, while false-pos-
itive variants resulted extremely variable and reported only 
in a single dataset in 71 % of cases, with only 6 % recur-
ring in more than half samples (Fig. 3d).
Estimation of filtering parameters in the HiQ datasets
Using the distributions of variant quality parameters esti-
mated above, we selected five parameters that better dis-
criminated true positives from false positives and we defined 
a set of thresholds that could be used to filter out false-pos-
itive calls (Fig. 4). For SNPs and indels separately we used 
the eight HiQ datasets from Ion Community to identify 
three sets of parameters corresponding to three levels of fil-
tering, namely high, medium and low-stringency filters, that 
should retain 90, 95 and 99 % of true positive calls, respec-
tively (Table 3). By applying these filters to NA12878_HiQ 
dataset, we obtained the predicted level of true positives 
and reduced the amount of false positives by 10.2, 21.2 and 
40.4 % for indels and 21.2, 41.9, 68.2 % for SNPs (Table 4).
Discussion
Characteristics and sequencing performances of the 
AmpliSeq Exome kit
The AmpliSeq Exome kit (Life Technologies) uses a 
multiplex-PCR approach to simultaneously generate 
Fig. 4  Study of parameters for variant filtering. We evaluated the 
distribution of 11 parameters reported by the TVC for indel (a) and 
SNP (b) variants identified from the HiQ datasets. AO alternate allele 
observation, DP read depth, FAO flow-space alternate allele observa-
tions, FDP flow space read depth, FXX flow evaluator failed reads 
ratio, GQ genotype quality, HRUN length of homopolymer, QD qual-
ity per read length, QUAL variant quality, STB strand bias ratio, STBP 
strand bias p value. The five parameters selected for filtering are 
reported as solid lines
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about 294,000 amplicons covering most of the CDS 
sequences in the human genome (Table 1; Fig. 1). The 
entire sequencing process, from library preparation to 
variant identification, can be completed in 48 h, thus 
providing a rapid method for exome investigation. The 
AmpliSeq Exome protocol on the Ion Proton platform 
showed robust sequencing results and the recently intro-
duced HiQ chemistry and PI v3 chip have improved the 
sequencing throughput to 16–17 Gb per run. The use 
of a PCR-based library preparation approach provides 
great specificity in target sequence enrichment, as indi-
cated by the percentage of on-target reads usually around 
90 %. This should also minimize the waste of sequenc-
ing throughput due to off-target data, enhancing the pro-
ductivity of the system. The analysis of coverage across 
the sequenced samples revealed high coverage uniformity, 
with most of the targeted bases represented in sequencing 
results also at lower mean coverage (Supplementary fig-
ure 2a, b). The analysis of the target regions addressed by 
AmpliSeq Exome kit revealed that it includes most of the 
bases present in human CDS sequences (~97 %). How-
ever, we found that up to 13 % of pathogenic genes from 
ClinVar could not be fully analyzed, a data that should 
be considered for diagnostic applications. This could be 
due to updated RefSeq annotations resulting in new exons 
placement or difficulties in amplicon design for certain 
genomic regions (see an example in Supplementary fig-
ure 1). The inability to fully capture the entire exome is 
a known issue (Bodi et al. 2013; Chilamakuri et al. 2014; 
Meienberg et al. 2015) and comparison among the main 
exome enrichment kits indicates SureSelect Human All 
Exon (Agilent Technologies) as the best one, particularly 
in terms of representation of medically relevant genes.
In the AmpliSeq Exome kit design most of the exons 
are addressed by one or two amplicons (Fig. 1b), thus the 
sequencing performance of each amplicon must be optimal 
to avoid loss of information on specific exons. One of the 
main factors influencing PCR amplification is the GC con-
tent of the amplified region and this parameter is also criti-
cal for NGS sequencing performance on both Illumina and 
Ion Torrent platforms (Liu et al. 2012; Quail et al. 2012; 
Ross et al. 2013). In our analysis, amplicons with a % GC 
content above 75 tend to fail in sequencing, resulting in a 
mean coverage below 10 across the analyzed samples (Sup-
plementary figure 2c, d). Instead, contrasting with previous 
studies on Ion Torrent PGM bacterial sequencing (Quail 
et al. 2012; Ross et al. 2013), we did not measure a sig-
nificant reduction in sequencing performances for ampli-
cons with low GC content. Our detailed analysis of the 
sequences included in the target regions, but affected by 
coverage issues, revealed that some of them are consistent 
across all samples, with 515 protein coding genes contain-
ing hard-to-sequence regions. These genes include also 90 
known genes reported as pathogenic, likely pathogenic or 
risk factors in ClinVar. The described issues on coverage 
and target regions confirm that is hard to obtain a complete 
picture of clinically-relevant genomic alterations when 
using exome sequencing solutions designed for research 
purposes (Meienberg et al. 2015). The high fraction of 
exons from ClinVar and ACMG genes completely missed 
by AmpliSeq Exome approach (Fig. 1c) suggests avoiding 
its use for clinical applications.
Table 3  Setting of filtering 
parameters
The settings of filtering parameters for low, medium and high-stringency filters are reported together with 
the % of true-positive calls (TP) retained using each filter
Stringency % TP retained GQ < x FDP < x QUAL < x HRUN > x FAO < x
INDELs
Low 99 5 10 20 6 4
Medium 95 8 20 30 5 4
High 90 10 25 40 4 4
Stringency % TP retained GQ < x FDP < x QUAL < x STB > x FAO < x
SNPs
Low 99 5 6 20 0.90 2
Medium 95 10 6 20 0.70 2
High 90 15 10 30 0.60 2
Table 4  Test of proposed filtering settings on NA12878 dataset
The table reports the % of true-positive (TP) and false-positive (FP) 










Low 99.2 21.2 98.9 10.2
Medium 96.1 41.9 95.1 21.2
High 89.9 68.2 89.8 40.4
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Accuracy in variants identification
Coverage metrics are one of the main factors influencing 
variant calling process (Hou et al. 2013; Sims et al. 2014; 
Kim et al. 2015), as also seen in our study. Our downsam-
pling analysis showed that, given an optimal sequencing 
library, a maximum in variants identification performance 
is reached above 120× mean coverage and that about 99 
and 95 % of true variants could be identified at 90 and 
70× mean coverage, respectively. Based on this analysis, 
three samples can be sequenced on a single PI v3 chip with 
high performance in variant calling, or up to four samples 
can be pooled together if sample size and not full detec-
tion of variants is critical for the study, as in genotyping 
approaches aggregating data from multiple samples for 
group comparisons.
To estimate the actual accuracy in variant identification 
provided by an AmpliSeq Exome sequencing experiment, 
we decided to compare our results on the NA12878 human 
reference sample with the latest version of the gold stand-
ard variant calls provided by GIAB Consortium (Zook et al. 
2014), a set of variants now broadly accepted as a stand-
ard for variant identification benchmarking. This analysis 
revealed a significant improvement from v3 chemistry to 
HiQ chemistry (Fig. 2), with F1 value increasing from ~0.3 
to ~0.65 and from ~0.94 to ~0.97 for indel and SNP vari-
ants, respectively. Previous studies comparing sequencing 
technologies have shown that variants identification is par-
ticularly difficult for indels on Ion Torrent data, with a high 
level of false-negative and false-positive calls (Jünemann 
et al. 2013; Boland et al. 2013). The HiQ chemistry data-
sets showed variant calling performance comparable with 
those obtained from the Illumina-based exome sequenc-
ing (Fig. 2) in terms of sensitivity. However, the Ion Pro-
ton platform confirmed to have more difficulties with indel 
calls and still produces a higher number of false-positive 
indels, with an FDR of ~35 %, significantly higher than the 
Illumina FDR of ~10 %.
The accuracy of variants identification was also strongly 
influenced by the read length profile of single experiment, 
with the loss of long fragments being the main issue. This 
could be explained by amplicon-based design of AmpliSeq 
Exome. Sequences produced from forward and reverse 
strands of each amplicon start at 3′ and 5′ ends of the 
addressed exon, so that shorter reads would result in low 
coverage at its center.
Overall, we also noted that the sensitivity for indel vari-
ants identification is ~70 % for both platforms, suggesting 
that a large fraction of actual indels would be missed in a 
standard exome sequencing experiment. This confirms pre-
vious findings reporting that specialized approaches in both 
sequencing and data analysis are required to effectively 
address this kind of variants.
Characterization of sequencing errors and filtering 
strategies
Given the increased sensitivity when using HiQ chemistry, 
the main bias affecting variants identified from AmpliSeq 
Exome sequencing experiment is the high proportion of 
false-positive calls. To address this issue, we analyzed in 
detail false-positive (FP), false-negative (FN) and true-pos-
itive (TP) calls and developed a filtering strategy to effec-
tively reduce the proportion of false positives. First of all, 
we analyzed for false-positive and true-positive variants 
the distribution of 11 variant quality parameters calculated 
by the Torrent Variant Caller. For both SNP and indel calls, 
we selected five parameters that could better discrimi-
nate erroneous calls (Fig. 4) and used them to develop a 
set of filters to remove false-positive calls. Depending 
on the desired level of sensitivity, high, medium or low-
stringency filters remove up to 68 and 40 % of false-pos-
itive SNPs and indels, respectively (see Tables 3, 4). The 
medium-stringency filter should be the best choice when 
analyzing single samples, as it retains more than 95 % TP 
variants and ensures a relevant reduction of FP variants 
that could confound subsequent variants interpretation. 
The low-stringency filter is recommended when consid-
ering pedigree data, where maximum sensitivity may be 
preferred to search for causative mutations and most of 
FP variants could be filtered out by segregation analysis. 
Finally, the high-stringency filter could be useful in large 
sequencing projects where the main focus is the global 
estimation of allele frequencies. In this case, the maximum 
reduction in FP variants could greatly enhance association 
analysis results, while the moderate loss of TP variants on 
single samples could be compensated by the large sample 
size.
Our analysis also revealed other peculiar aspects of erro-
neous indel calls, the major class of variant error reported 
for the Ion Torrent technology. Even if they may not be 
used for filtering, they could be used to prioritize indel 
variants in downstream analysis. As previously described 
for the Ion Torrent sequencing (Liu et al. 2012; Quail et al. 
2012), also in our HiQ datasets most of the false-positive 
indels were short insertions/deletions of 1–2 bp (Fig. 3c). 
False-positive indels tend to occur with multiple alternate 
alleles in VCF files, mainly due to short homopolymer 
or triplet repeats erroneously identified as multiple indel 
alleles with different lengths. Particularly, indels presenting 
three or more alternate alleles have a high probability to be 
false positives. Concerning false-negative calls in our data-
sets, they are only partially explained by coverage issues 
(Fig. 3b). Triplet repetitions and homopolymeric regions 
are recurrent among missed variants, confirming that these 
kinds of variants are difficult to be detected using NGS 
technologies (Allhoff et al. 2013).
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Finally, we analyzed recurrence of false-positive and 
true-positive variants across the nine HiQ datasets. True-
positive variants showed to be highly consistent through the 
datasets, while false-positive variants resulted extremely 
variable and mostly reported only in a single dataset 
(Fig. 3d). This supports the hypothesis that false-positive 
calls, especially indels, are mainly represented by random 
errors associated to the high ratio of indels/read produced 
by the Ion Torrent sequencing technology (Bragg et al. 
2013). The run-specific nature of false positives also sug-
gests that an experimental design based on sequencing rep-
licates of the same library could be an effective strategy to 
improve variant identification and filter out false variants.
Conclusions
Amplicon-based exome sequencing on the Ion Pro-
ton platform provides rapid and cost-effective exome 
sequencing on human samples. Improved accuracy and 
sequencing throughput thanks to the latest HiQ chemis-
try and PI v3 chip provide good flexibility in experimen-
tal design, increasing productivity up to four samples per 
run, while maintaining acceptable performance in terms 
of variants identification. However, as in exome enrich-
ment products from main competitors, the full exome 
cannot be completely addressed by AmpliSeq Exome 
kit, due to limitations in both target region PCR amplifi-
cation and sequencing performance on specific genomic 
regions. Researchers should carefully consider the best 
exome enrichment kit based on their region of interest 
and here we provide a useful guide to assess missed exons 
in AmpliSeq Exome kit (Supplementary tables 1 and 9). 
Even if false-positive variants remain major issues in vari-
ant calling for the Ion Torrent technology, our analysis 
provides a useful filtering strategy to reduce their num-
ber. We identified a set of filters and peculiar properties 
characterizing false-positive variants that could be used 
together to significantly enhance performance in exome 
variants analysis.
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